Skip to main content
SpringerLink
Log in

Advanced Prostate Cancer Consensus Conference 2017

Diskussion der Empfehlungen zur Diagnostik und Therapie des metastasierten Prostatakarzinoms durch ein deutsches Expertengremium

Advanced Prostate Cancer Consensus Conference 2017

Discussion of the recommendations for diagnosis and treatment of metastatic prostate cancer by a German panel of experts

  • Originalien
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Im März 2017 fand die Advanced Prostate Cancer Consensus Conference (APCCC) in St. Gallen (Schweiz) statt. Vor dem Hintergrund der aktuellen Datenlage diskutierte das APCCC-Panel, das sich aus international renommierten Experten zusammensetzt, die Behandlung des fortgeschrittenen Prostatakarzinoms mit dem Ziel, die internationale APCCC-Konsensusempfehlungen aus dem Jahr 2015 zu aktualisieren und neue relevante Aspekte zu diskutieren. Die aktuellen Konsensusempfehlungen wurden zwischenzeitlich in der Fachzeitschrift European Urology der EAU (European Association of Urology) publiziert. Ein deutsches Expertengremium hat die Ergebnisse der APCCC-Konsensusabstimmungen aus deutscher Sicht kommentiert. Rationale hierfür ist, dass internationale Empfehlungen auch von länderspezifischen Eigenheiten beeinflusst sind und dass die zur Abstimmung gestellten Fragen nicht immer ausreichend präzisiert sein können. Im Fokus der diesjährigen Konsensusdiskussion stand u. a. die Behandlung des metastasierten kastrationsnaiven Prostatakarzinoms (mCNPC). Hier liegen neue Studiendaten vor, welche die Therapiesituation des metastasierten kastrationsresistenten Prostatakarzinoms (mCRPC) beeinflussen können. Weitere Diskussionsschwerpunkte waren der Stellenwert der neuen bildgebenden Verfahren für den klinischen Alltag sowie die Behandlung des oligometastasierten Prostatakarzinoms.

Abstract

In March 2017 the ‚Advanced Prostate Cancer Consensus Conference‘ (APCCC) took place in St. Gallen (Switzerland). The APCCC-panelists are internationally well known experts. With the actual data in mind they discussed treatment options for patients with advanced prostate cancer in order to update the international APCCC-recommendations from the previous meeting in 2015. Recently these consensus recommendations have been published in “European Urology”.

A group of German experts discussed this year APCCC-votes during the meeting and the recommendations that were concluded from the votes from the German perspective. Reasons for an additional German discussion are country-specific variations that may have influenced the APCCC-votes und recommendations. Due to the concept of the APCCC-meeting the wording of the questions could not always be as necessary.

One focus of this year consensus discussion was the treatment of metastatic castration-naive prostate cancer (mCNPC). There are new data which may also influence the therapeutic situation of patients with metastatic castration-resistant prostate cancer (mCRPC). Further points of discussion were the impact of new imaging procedures in the clinical setting as well as the treatment of oligometastatic prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Aapro MS, Bohlius J, Cameron DA et al (2011) Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32

    Article  PubMed  CAS  Google Scholar 

  2. Abdollah F, Karnes RJ, Suardi N et al (2014) Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol 32(35):3939–3947

    Article  PubMed  Google Scholar 

  3. Attard G (2017) A phase IV, randomised double-blind placebo-controlled study of continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naïve metastatic castrations-resistant prostate cancer. J Clin Oncol. https://doi.org/10.1200/JCO.2017.35.15_suppl.5004

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bader P, Burkhard FC, Markwalder R, Studer UE (2003) Disease progression and survival of patients with positive lymphe nodes after radical prostatectomy. Is there a chance of cure? J Urol 169(3):849–854

    Article  PubMed  Google Scholar 

  5. Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Berthold DR, Pond GR, soban F et al (2008) Docetaxel plus prednisone or mitoxantron plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245

    Article  PubMed  CAS  Google Scholar 

  7. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus Cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    Article  PubMed  CAS  Google Scholar 

  8. de Bono JS, Hardy-Bessard AC, Kim CS et al (2016) Phase III non-inferiority study of Cabazitaxel 20 mg/m² versus 25 mg/m² in patients with metastatic castration resistant prostate cancer previously treated with docetaxel. J Clin Oncol. https://doi.org/10.1200/JCO.2016.34.15_suppl.5008

    Article  PubMed  PubMed Central  Google Scholar 

  9. Sanofi-Aventis Deutschland GmbH. Fachinformation Jevtana®, Stand: Mai 2017.

  10. Fizazi K, Scher HI, Molina AM et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised double-blind placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992

    Article  PubMed  CAS  Google Scholar 

  11. Fizazi K, Tran NP, Fein L et al (2017) Abiraterone plus Prednisone in metastatic castration-sensitive prostate cancer. N Engl J Med 377(4):352–360

    Article  PubMed  CAS  Google Scholar 

  12. Fossati N, Karnes RJ, Czzarini C et al (2016) Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol 69(4):728–733

    Article  PubMed  Google Scholar 

  13. Gillessen S, Attard G, Beer T et al (2017) Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. https://doi.org/10.1016/j.eururo.2017.06.002

    Article  PubMed  Google Scholar 

  14. Heidenreich A, Pfister D, Thüer D et al (2011) Percentage of positive biopsies predicts lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extended pelvic lymph-adenectomy. BJU Int 107(2):220–225

    Article  PubMed  Google Scholar 

  15. James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage platform randomised controlled trial. Lancet 387:1163–1177

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Karl A, Buchner A, Tympner C (2015) The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence. World J Urol 33(7):973–979

    Article  PubMed  CAS  Google Scholar 

  17. Lavaud P, Gravis G, Foulon S et al (2017) Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without Docetaxl for metastatic castration-naive prostate cancer in the GETUG-AFU 15 phase 3 trial. Eur Urol. https://doi.org/10.1016/j.eururo.2017.09.022

    Article  PubMed  Google Scholar 

  18. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2018) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.0, 2018, AWMF Registernummer: 043/022OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/. Zugegriffen: 29. Apr. 2018

    Google Scholar 

  19. Maines F, Caffo O, Veccia A et al (2015) Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol 96:498–506

    Article  PubMed  Google Scholar 

  20. Oudard S (2011) TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol 7:497–506

    Article  PubMed  CAS  Google Scholar 

  21. Perera M, Papa N, Christidis D et al (2016) Sensitivity, specificity, and predictors of positive 68 ga-prostate-specific membrane antigenpositron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70(6):926–937

    Article  PubMed  Google Scholar 

  22. Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148

    Article  PubMed  CAS  Google Scholar 

  23. Sartor AO, Oudard S, Sengelov L et al (2016) Cabazitaxel versus docetaxel in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a three-arm phase III study (FIRSTANA). J Clin Oncol. https://doi.org/10.1200/JCO.2016.34.15_suppl.5006

    Article  PubMed  PubMed Central  Google Scholar 

  24. Scher HI, Fizazi K, Saad PD et al (2012) Increased survival with Enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197

    Article  PubMed  CAS  Google Scholar 

  25. Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastaic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantron plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  27. Verburg FA, Pfister D, Heidenreich A et al (2016) Extent of disease in recurrent prostate cancer determined by [(68)GA] PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason Score. Eur J Nucl Med Mol Imaging 43(3):397–403

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Universitätsklinikum der Otto-von-Guericke-Universität, Leipziger Straße 44, 39120, Magdeburg, Deutschland

    M. Schostak

  2. ATURO, Facharztzentrum für Urologie, Berlin, Deutschland

    F. König

  3. Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Münster, Deutschland

    M. Bögemann

  4. Urologische und Kinderurologische Klinik, Universitätsklinikum Erlangen, Erlangen, Deutschland

    P. Goebell

  5. Klinik für Urologie und Uroonkologie, Städtisches Klinikum Braunschweig, Braunschweig, Deutschland

    P. Hammerer

  6. Klinik für Urologie und Kinderurologie, Marien-Krankenhaus Bergisch Gladbach, Bergisch Gladbach, Deutschland

    S. Machtens

  7. Urologische Klinik, Diakonie-Klinikum Stuttgart, Stuttgart, Deutschland

    C. Schwentner

  8. Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsmedizin Mainz, Mainz, Deutschland

    C. Thomas

  9. Klinik für Onkologie, Hämatologie und Knochenmarkstransplantation, Onkologisches Zentrum, Universitätsklinikum Hamburg, Hamburg, Deutschland

    G. von Amsberg

  10. Klinik für Urologie, Universitätsklinikum Jena, Jena, Deutschland

    F.-C. von Rundstedt

  11. Klinik für Urologie, Uro-Onkologie, Roboter-assistierte und Spezielle Urologische Chirurgie, Universitätsklinikum Köln, Köln, Deutschland

    A. Heidenreich

Authors
  1. M. Schostak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. König
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Bögemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Goebell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Hammerer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Machtens
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Schwentner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. von Amsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F.-C. von Rundstedt
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Heidenreich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Schostak.

Ethics declarations

Interessenkonflikt

M. Schostak, F. König, M. Bögemann, P. Goebell, P. Hammerer, S. Machtens, C. Schwentner, C. Thomas, G. von Amsberg, F.-C. von Rundstedt und A. Heidenreich geben an, dass kein Interessenkonflikt besteht. Das Expertentreffen, welches als Basis der Publikation diente, wurde organisiert und finanziert von Sanofi-Aventis.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Die Autoren M. Schostak und F. König haben zu gleichen Teilen zum Manuskript beigetragen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schostak, M., König, F., Bögemann, M. et al. Advanced Prostate Cancer Consensus Conference 2017. Urologe 57, 813–820 (2018). https://doi.org/10.1007/s00120-018-0680-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-018-0680-9

Schlüsselwörter

Keywords

Search

Navigation